Skip to main content
SpringerLink
Log in

Psoriasis and Comorbidities

  • Chapter
  • First Online:
Advances in Psoriasis

Abstract

Psoriasis is increasingly recognised as one of a group of immune-mediated inflammatory diseases (IMIDs) with overlapping pathogenesis. The ability to detect diseases associated with psoriasis has been complemented through interrogation of large datasets utilising genome wide association scans to demonstrate overlapping genetic risk factors of associated diseases. Many of these associated conditions, such as psoriatic arthritis and inflammatory bowel disease have a significant impact on morbidity. In addition the inflammatory burden associated with psoriasis is associated with a myriad of systemic sequalae including higher levels of cardiovascular risk. This provides the dermatologist with an opportunity to holistically treat a patient and to promote relevant primary and secondary care prevention strategies. Additionally, effective control of the inflammatory burden of psoriasis may modify the risk of comorbidities associated with psoriasis and would support earlier use of immunomodulatory therapies. This chapter will cover the comorbidities (including cardiovascular disease [CVD], metabolic syndrome and malignancy) associated with psoriasis and consider how these factors may influence or impact on management of the patient.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 129.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. (07/25/2019) hwcgodahla.

    Google Scholar 

  2. Lawlor DA, Lean M, Sattar N. ABC of obesity: obesity and vascular disease. Br Med J. 2006;333(7577):1060–3.

    Article  Google Scholar 

  3. McMillan DC, Sattar N, McArdle CS. ABC of obesity. Obesity and cancer. Br Med J. 2006;333(7578):1109–11.

    Article  Google Scholar 

  4. Hossain P, Kawar B, El Nahas M. Obesity and diabetes in the developing world—a growing challenge. N Engl J Med. 2007;356(3):213–5.

    Article  CAS  PubMed  Google Scholar 

  5. Wellen KE, Hotamisligil GS. Obesity-induced inflammatory changes in adipose tissue. J Clin Invest. 2003;112(12):1785–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Matsuzawa Y. The role of fat topology in the risk of disease. Int J Obes. 2008;32(Suppl 7):S83–92.

    Article  CAS  Google Scholar 

  7. Rivers JP, Powell-Wiley TM, Dey AK, et al. Visceral adiposity in psoriasis is associated with vascular inflammation by (18)F-fluorodeoxyglucose positron-emission tomography/computed tomography beyond cardiometabolic disease risk factors in an observational cohort study. JACC Cardiovasc Imaging. 2018;11(2 Pt 2):349–57.

    Article  PubMed  Google Scholar 

  8. Lindegard B. Diseases associated with psoriasis in a general population of 159,200 middle-aged, urban, native Swedes. Dermatologica. 1986;172(6):298–304.

    Article  CAS  PubMed  Google Scholar 

  9. Henseler T, Christophers E. Disease concomitance in psoriasis. J Am Acad Dermatol. 1995;32(6):982–6.

    Article  CAS  PubMed  Google Scholar 

  10. Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB, Gelfand JM. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol. 2006;55(5):829–35.

    Article  PubMed  Google Scholar 

  11. Cohen AD, Sherf M, Vidavsky L, Vardy DA, Shapiro J, Meyerovitch J. Association between psoriasis and the metabolic syndrome. A cross-sectional study. Dermatology. 2008;216(2):152–5.

    Article  CAS  PubMed  Google Scholar 

  12. Kaye JA, Li L, Jick SS. Incidence of risk factors for myocardial infarction and other vascular diseases in patients with psoriasis. Br J Dermatol. 2008;159(4):895–902.

    Article  CAS  PubMed  Google Scholar 

  13. Shapiro J, Cohen AD, Weitzman D, Tal R, David M. Psoriasis and cardiovascular risk factors: a case-control study on inpatients comparing psoriasis to dermatitis. J Am Acad Dermatol. 2012;66(2):252–8.

    Article  PubMed  Google Scholar 

  14. Augustin M, Reich K, Glaeske G, Schaefer I, Radtke M. Co-morbidity and age-related prevalence of psoriasis: analysis of health insurance data in Germany. Acta Derm Venereol. 2010;90(2):147–51.

    Article  PubMed  Google Scholar 

  15. Huerta C, Rivero E, Rodriguez LA. Incidence and risk factors for psoriasis in the general population. Arch Dermatol. 2007;143(12):1559–65.

    Article  PubMed  Google Scholar 

  16. Langan SM, Seminara NM, Shin DB, et al. Prevalence of metabolic syndrome in patients with psoriasis: a population-based study in the United Kingdom. J Invest Dermatol. 2012;132(3):556–62.

    Article  CAS  PubMed  Google Scholar 

  17. Snekvik I, Smith CH, Nilsen TIL, et al. Obesity, waist circumference, weight change, and risk of incident psoriasis: prospective data from the HUNT Study. J Invest Dermatol. 2017;137(12):2484–90.

    Article  CAS  PubMed  Google Scholar 

  18. Han JH, Lee JH, Han KD, et al. Increased risk of psoriasis in subjects with abdominal obesity: a nationwide population-based study. J Dermatol. 2019;46(8):695–701.

    Article  PubMed  Google Scholar 

  19. Cohen AD, Dreiher J, Shapiro Y, et al. Psoriasis and diabetes: a population-based cross-sectional study. J Eur Acad Dermatol Venereol. 2008;22(5):585–9.

    Article  CAS  PubMed  Google Scholar 

  20. Herron MD, Hinckley M, Hoffman MS, et al. Impact of obesity and smoking on psoriasis presentation and management. Arch Dermatol. 2005;141(12):1527–34.

    Article  PubMed  Google Scholar 

  21. Kimball AB, Szapary P, Mrowietz U, et al. Underdiagnosis and undertreatment of cardiovascular risk factors in patients with moderate to severe psoriasis. J Am Acad Dermatol. 2012;67(1):76–85.

    Article  PubMed  Google Scholar 

  22. Setty AR, Curhan G, Choi HK. Obesity, waist circumference, weight change, and the risk of psoriasis in women: Nurses’ Health Study II. Arch Intern Med. 2007;167(15):1670–5.

    Article  PubMed  Google Scholar 

  23. Naldi L, Chatenoud L, Linder D, et al. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol. 2005;125(1):61–7.

    Article  CAS  PubMed  Google Scholar 

  24. Davidovici BB, Sattar N, Prinz JC, et al. Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. J Invest Dermatol. 2010;130(7):1785–96.

    Article  CAS  PubMed  Google Scholar 

  25. Liu Y, Krueger JG, Bowcock AM. Psoriasis: genetic associations and immune system changes. Genes Immun. 2007;8(1):1–12.

    Article  PubMed  CAS  Google Scholar 

  26. Zaba LC, Cardinale I, Gilleaudeau P, et al. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med. 2007;204(13):3183–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Bastard JP, Maachi M, Lagathu C, et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw. 2006;17(1):4–12.

    CAS  PubMed  Google Scholar 

  28. Kanneganti TD, Dixit VD. Immunological complications of obesity. Nat Immunol. 2012;13(8):707–12.

    Article  CAS  PubMed  Google Scholar 

  29. Endo Y, Yokote K, Nakayama T. The obesity-related pathology and Th17 cells. Cell Mol Life Sci. 2017;74(7):1231–45.

    Article  CAS  PubMed  Google Scholar 

  30. Ryan AS, Nicklas BJ. Reductions in plasma cytokine levels with weight loss improve insulin sensitivity in overweight and obese postmenopausal women. Diabetes Care. 2004;27(7):1699–705.

    Article  PubMed  Google Scholar 

  31. Hamminga EA, van der Lely AJ, Neumann HA, Thio HB. Chronic inflammation in psoriasis and obesity: implications for therapy. Med Hypotheses. 2006;67(4):768–73.

    Article  CAS  PubMed  Google Scholar 

  32. de Menezes Ettinger JE, Azaro E, de Souza CA, et al. Remission of psoriasis after open gastric bypass. Obes Surg. 2006;16(1):94–7.

    Article  PubMed  Google Scholar 

  33. Upala S, Sanguankeo A. Effect of lifestyle weight loss intervention on disease severity in patients with psoriasis: a systematic review and meta-analysis. Int J Obes. 2015;39(8):1197–202.

    Article  CAS  Google Scholar 

  34. Li RC, Krishnamoorthy P, DerOhannessian S, et al. Psoriasis is associated with decreased plasma adiponectin levels independently of cardiometabolic risk factors. Clin Exp Dermatol. 2014;39(1):19–24.

    Article  PubMed  Google Scholar 

  35. Gerdes S, Rostami-Yazdi M, Mrowietz U. Adipokines and psoriasis. Exp Dermatol. 2011;20(2):81–7.

    Article  CAS  PubMed  Google Scholar 

  36. Li W, Man XY. Linear psoriasis. CMAJ. 2012;184(7):789.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Chen K, Craig JC, Shumack S. Oral retinoids for the prevention of skin cancers in solid organ transplant recipients: a systematic review of randomized controlled trials. Br J Dermatol. 2005;152(3):518–23.

    Article  CAS  PubMed  Google Scholar 

  38. Naldi L, Addis A, Chimenti S, et al. Impact of body mass index and obesity on clinical response to systemic treatment for psoriasis. Evidence from the Psocare project. Dermatology. 2008;217(4):365–73.

    Article  PubMed  Google Scholar 

  39. Tan E, Baker C, Foley P. Weight gain and tumour necrosis factor-alpha inhibitors in patients with psoriasis. Australas J Dermatol. 2013;54(4):259–63.

    Article  PubMed  Google Scholar 

  40. Zhu Y, Hu C, Lu M, et al. Population pharmacokinetic modeling of ustekinumab, a human monoclonal antibody targeting IL-12/23p40, in patients with moderate to severe plaque psoriasis. J Clin Pharmacol. 2009;49(2):162–75.

    Article  CAS  PubMed  Google Scholar 

  41. Weisman MH, Moreland LW, Furst DE, et al. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. Clin Ther. 2003;25(6):1700–21.

    Article  CAS  PubMed  Google Scholar 

  42. Clark L, Lebwohl M. The effect of weight on the efficacy of biologic therapy in patients with psoriasis. J Am Acad Dermatol. 2008;58(3):443–6.

    Article  PubMed  Google Scholar 

  43. Menter A, Gordon K, Goldblum O, Gu Y. Efficacy and safety of adalimumab are consistent across weight quartiles in patients with moderate to severe psoriasis: subanalysis of REVEAL. J Am Acad Dermatol. 2009;54(Suppl):S101–11.

    Google Scholar 

  44. Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008;371(9625):1675–84.

    Article  CAS  PubMed  Google Scholar 

  45. Laws PM, Downs AM, Parslew R, et al. Practical experience of ustekinumab in the treatment of psoriasis: experience from a multicentre, retrospective case cohort study across the U.K. and Ireland. Br J Dermatol. 2012;166(1):189–95.

    Article  CAS  PubMed  Google Scholar 

  46. Wu JJ, Channual JC, Dann F. Association of systemic psoriasis therapies and incidence of myocardial infarction. Br J Dermatol. 2012;166(1):232. author reply 233

    Article  CAS  PubMed  Google Scholar 

  47. Reich K, Puig L, Mallbris L, Zhang L, Osuntokun O, Leonardi C. The effect of bodyweight on the efficacy and safety of ixekizumab: results from an integrated database of three randomised, controlled phase 3 studies of patients with moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol. 2017;31(7):1196–207.

    Article  CAS  PubMed  Google Scholar 

  48. Paul C, Cather J, Gooderham M, et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2). Br J Dermatol. 2015;173(6):1387–99.

    Article  CAS  PubMed  Google Scholar 

  49. Dreiher J, Weitzman D, Davidovici B, Shapiro J, Cohen AD. Psoriasis and dyslipidaemia: a population-based study. Acta Derm Venereol. 2008;88(6):561–5.

    CAS  PubMed  Google Scholar 

  50. Tsai TF, Wang TS, Hung ST, et al. Epidemiology and comorbidities of psoriasis patients in a national database in Taiwan. J Dermatol Sci. 2011;63(1):40–6.

    Article  PubMed  Google Scholar 

  51. Yang YW, Keller JJ, Lin HC. Medical comorbidity associated with psoriasis in adults: a population-based study. Br J Dermatol. 2011;165(5):1037–43.

    Article  PubMed  Google Scholar 

  52. Wu Y, Mills D, Bala M. Psoriasis: cardiovascular risk factors and other disease comorbidities. J Drugs Dermatol. 2008;7(4):373–7.

    PubMed  Google Scholar 

  53. Kimball AB, Gladman D, Gelfand JM, et al. National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. J Am Acad Dermatol. 2008;58(6):1031–42.

    Article  PubMed  PubMed Central  Google Scholar 

  54. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006;296(14):1735–41.

    Article  CAS  PubMed  Google Scholar 

  55. Fernández-Armenteros JM, Gómez-Arbonés X, Buti-Soler M, et al. Psoriasis, metabolic syndrome and cardiovascular risk factors. A population-based study. J Eur Acad Dermatol Venereol. 2019;33(1):128–35.

    Article  PubMed  Google Scholar 

  56. Al-Mutairi N, Al-Farag S, Al-Mutairi A, Al-Shiltawy M. Comorbidities associated with psoriasis: an experience from the Middle East. J Dermatol. 2010;37(2):146–55.

    Article  PubMed  Google Scholar 

  57. Kimball AB, Robinson D Jr, Wu Y, et al. Cardiovascular disease and risk factors among psoriasis patients in two US healthcare databases, 2001–2002. Dermatology. 2008;217(1):27–37.

    Article  CAS  PubMed  Google Scholar 

  58. Prey S, Paul C, Bronsard V, et al. Cardiovascular risk factors in patients with plaque psoriasis: a systematic review of epidemiological studies. J Eur Acad Dermatol Venereol. 2010;24(Suppl 2):23–30.

    Article  PubMed  Google Scholar 

  59. Mallbris L, Granath F, Hamsten A, Stahle M. Psoriasis is associated with lipid abnormalities at the onset of skin disease. J Am Acad Dermatol. 2006;54(4):614–21.

    Article  PubMed  Google Scholar 

  60. Shrestha A, Bahce-Altuntas A, Mowrey W, Broder A. Active peripheral inflammation is associated with pro-atherogenic lipid profile in psoriatic arthritis. Semin Arthritis Rheum. 2016;46(3):286–90.

    Article  CAS  PubMed  Google Scholar 

  61. Holzer M, Wolf P, Inzinger M, et al. Anti-psoriatic therapy recovers high-density lipoprotein composition and function. J Invest Dermatol. 2014;134(3):635–42.

    Article  CAS  PubMed  Google Scholar 

  62. Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58(5):826–50.

    Article  PubMed  Google Scholar 

  63. Wan J, Abuabara K, Troxel AB, et al. Dermatologist preferences for first-line therapy of moderate to severe psoriasis in healthy adult patients. J Am Acad Dermatol. 2012;66(3):376–86.

    Article  PubMed  Google Scholar 

  64. Mehta NN, Yu Y, Saboury B, et al. Systemic and vascular inflammation in patients with moderate to severe psoriasis as measured by [18F]-fluorodeoxyglucose positron emission tomography-computed tomography (FDG-PET/CT): a pilot study. Arch Dermatol. 2011;147(9):1031–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Shah K, Mellars L, Changolkar A, Feldman SR. Real-world burden of comorbidities in US patients with psoriasis. J Am Acad Dermatol. 2017;77(2):287–292.e4.

    Article  PubMed  Google Scholar 

  66. Gelfand JM, Dommasch ED, Shin DB, et al. The risk of stroke in patients with psoriasis. J Invest Dermatol. 2009;129(10):2411–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Cohen AD, Weitzman D, Dreiher J. Psoriasis and hypertension: a case-control study. Acta Derm Venereol. 2010;90(1):23–6.

    Article  PubMed  Google Scholar 

  68. Armstrong AW, Harskamp CT, Armstrong EJ. The association between psoriasis and hypertension: a systematic review and meta-analysis of observational studies. J Hypertens. 2013;31(3):433–42. discussion 442–433

    Article  CAS  PubMed  Google Scholar 

  69. Kim HN, Han K, Song SW, Lee JH. Hypertension and risk of psoriasis incidence: an 11-year nationwide population-based cohort study. PLoS One. 2018;13(8):e0202854.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  70. Wakkee M, Thio HB, Prens EP, Sijbrands EJ, Neumann HA. Unfavorable cardiovascular risk profiles in untreated and treated psoriasis patients. Atherosclerosis. 2007;190(1):1–9.

    Article  CAS  PubMed  Google Scholar 

  71. Ena P, Madeddu P, Glorioso N, Cerimele D, Rappelli A. High prevalence of cardiovascular diseases and enhanced activity of the renin-angiotensin system in psoriatic patients. Acta Cardiol. 1985;40(2):199–205.

    CAS  PubMed  Google Scholar 

  72. Ryder KW, Epinette WW, Jay SJ, Ransburg RC, Glick MR. Serum angiotensin converting enzyme activity in patients with psoriasis. Clin Chim Acta. 1985;153(2):143–6.

    Article  CAS  PubMed  Google Scholar 

  73. Bonifati C, Mussi A, Carducci M, et al. Endothelin-1 levels are increased in sera and lesional skin extracts of psoriatic patients and correlate with disease severity. Acta Derm Venereol. 1998;78(1):22–6.

    Article  CAS  PubMed  Google Scholar 

  74. Rutter MK, Kane K, Lunt M, et al. Primary care-based screening for cardiovascular risk factors in patients with psoriasis. Br J Dermatol. 2016;175(2):348–56.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. Preiss D, Sattar N. Non-alcoholic fatty liver disease: an overview of prevalence, diagnosis, pathogenesis and treatment considerations. Clin Sci (Lond). 2008;115(5):141–50.

    Article  CAS  Google Scholar 

  76. Gisondi P, Targher G, Zoppini G, Girolomoni G. Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol. 2009;51(4):758–64.

    Article  CAS  PubMed  Google Scholar 

  77. Gisondi P, Barba E, Girolomoni G. Non-alcoholic fatty liver disease fibrosis score in patients with psoriasis. J Eur Acad Dermatol Venereol. 2016;30(2):282–7.

    Article  CAS  PubMed  Google Scholar 

  78. Abedini R, Salehi M, Lajevardi V, Beygi S. Patients with psoriasis are at a higher risk of developing nonalcoholic fatty liver disease. Clin Exp Dermatol. 2015;40(7):722–7.

    Article  CAS  PubMed  Google Scholar 

  79. Miele L, Vallone S, Cefalo C, et al. Prevalence, characteristics and severity of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol. 2009;51(4):778–86.

    Article  CAS  PubMed  Google Scholar 

  80. van der Voort EA, Koehler EM, Nijsten T, et al. Increased prevalence of advanced liver fibrosis in patients with psoriasis: a cross-sectional analysis from the Rotterdam Study. Acta Derm Venereol. 2016;96(2):213–7.

    Article  PubMed  CAS  Google Scholar 

  81. Phan K, Onggo J, Charlton O, Smith SD. Relationship between psoriasis and non-alcoholic fatty liver disease—updated systematic review and adjusted meta-analysis. Australas J Dermatol. 2019;60(4):e352–5.

    Article  PubMed  Google Scholar 

  82. Wenk KS, Arrington KC, Ehrlich A. Psoriasis and non-alcoholic fatty liver disease. J Eur Acad Dermatol Venereol. 2011;25(4):383–91.

    Article  CAS  PubMed  Google Scholar 

  83. Cheng D. Prevalence, predisposition and prevention of type II diabetes. Nutr Metab (Lond). 2005;2:29.

    Article  CAS  Google Scholar 

  84. Wannamethee SG, Shaper AG, Lennon L, Morris RW. Metabolic syndrome vs Framingham Risk Score for prediction of coronary heart disease, stroke, and type 2 diabetes mellitus. Arch Intern Med. 2005;165(22):2644–50.

    Article  PubMed  Google Scholar 

  85. Cheng J, Kuai D, Zhang L, Yang X, Qiu B. Psoriasis increased the risk of diabetes: a meta-analysis. Arch Dermatol Res. 2012;304(2):119–25.

    Article  PubMed  Google Scholar 

  86. Armstrong AW, Harskamp CT, Armstrong EJ. Psoriasis and the risk of diabetes mellitus: a systematic review and meta-analysis. JAMA Dermatol. 2013;149(1):84–91.

    Article  PubMed  Google Scholar 

  87. Wan MT, Shin DB, Hubbard RA, Noe MH, Mehta NN, Gelfand JM. Psoriasis and the risk of diabetes: a prospective population-based cohort study. J Am Acad Dermatol. 2018;78(2):315–322.e1.

    Article  PubMed  Google Scholar 

  88. Boehncke S, Thaci D, Beschmann H, et al. Psoriasis patients show signs of insulin resistance. Br J Dermatol. 2007;157(6):1249–51.

    Article  CAS  PubMed  Google Scholar 

  89. Boehncke S, Salgo R, Garbaraviciene J, et al. Effective continuous systemic therapy of severe plaque-type psoriasis is accompanied by amelioration of biomarkers of cardiovascular risk: results of a prospective longitudinal observational study. J Eur Acad Dermatol Venereol. 2011;25(10):1187–93.

    Article  CAS  PubMed  Google Scholar 

  90. Wolf N, Quaranta M, Prescott NJ, et al. Psoriasis is associated with pleiotropic susceptibility loci identified in type II diabetes and Crohn disease. J Med Genet. 2008;45(2):114–6.

    Article  CAS  PubMed  Google Scholar 

  91. Warren RB, Smith RL, Flynn E, et al. A systematic investigation of confirmed autoimmune loci in early-onset psoriasis reveals an association with IL2/IL21. Br J Dermatol. 2011;164(3):660–4.

    CAS  PubMed  Google Scholar 

  92. Wang H, Wang Z, Rani PL, et al. Identification of PTPN22, ST6GAL1 and JAZF1 as psoriasis risk genes demonstrates shared pathogenesis between psoriasis and diabetes. Exp Dermatol. 2017;26(11):1112–7.

    Article  CAS  PubMed  Google Scholar 

  93. Brauchli YB, Jick SS, Curtin F, Meier CR. Association between use of thiazolidinediones or other oral antidiabetics and psoriasis: a population based case-control study. J Am Acad Dermatol. 2008;58(3):421–9.

    Article  PubMed  Google Scholar 

  94. Brauchli YB, Jick SS, Meier CR. Statin use and risk of first-time psoriasis diagnosis. J Am Acad Dermatol. 2011;65(1):77–83.

    Article  PubMed  Google Scholar 

  95. Chang YC, Wu WM, Hsu LA. Lack of association between the genetic variations in the C-reactive protein gene and the risk of psoriasis among the Taiwanese. Mol Biol Rep. 2012;39(4):4111–7.

    Article  CAS  PubMed  Google Scholar 

  96. Wagner L, Klemann C, Stephan M, von Horsten S. Unravelling the immunological roles of dipeptidyl peptidase 4 (DPP4) activity and/or structure homologue (DASH) proteins. Clin Exp Immunol. 2016;184(3):265–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  97. Hong JR, Lee YW, Choe YB, Ahn KJ. Risk factors for increased serum creatinine level in patients with psoriasis treated with cyclosporine in a real-world practice. Dermatol Ther. 2019;32(3):e12875.

    Article  PubMed  Google Scholar 

  98. Kalb RE, Strober B, Weinstein G, Lebwohl M. Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference. J Am Acad Dermatol. 2009;60(5):824–37.

    Article  PubMed  Google Scholar 

  99. Armstrong AW, Guerin A, Sundaram M, et al. Psoriasis and risk of diabetes-associated microvascular and macrovascular complications. J Am Acad Dermatol. 2015;72(6):968–977.e2.

    Article  PubMed  Google Scholar 

  100. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005;365(9468):1415–28.

    Article  CAS  PubMed  Google Scholar 

  101. Kahn R. Metabolic syndrome: is it a syndrome? Does it matter? Circulation. 2007;115(13):1806–10. discussion 1811

    Article  PubMed  Google Scholar 

  102. Expert Panel on Detection, Evaluation. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486–97.

    Article  Google Scholar 

  103. Balkau B, Eschwege E. Insulin resistance: an independent risk factor for cardiovascular disease? Diabetes Obes Metab. 1999;1(Suppl 1):S23–31.

    Article  PubMed  Google Scholar 

  104. Choudhury J, Sanyal AJ. Insulin resistance and the pathogenesis of nonalcoholic fatty liver disease. Clin Liver Dis. 2004;8(3):575–94, ix.

    Article  PubMed  Google Scholar 

  105. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002;287(3):356–9.

    Article  PubMed  Google Scholar 

  106. Grundy SM, Hansen B, Smith SC Jr, Cleeman JI, Kahn RA. Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. Circulation. 2004;109(4):551–6.

    Article  PubMed  Google Scholar 

  107. Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001;24(4):683–9.

    Article  CAS  PubMed  Google Scholar 

  108. Malik S, Wong ND, Franklin SS, et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation. 2004;110(10):1245–50.

    Article  PubMed  Google Scholar 

  109. Hu G, Qiao Q, Tuomilehto J, Balkau B, Borch-Johnsen K, Pyorala K. Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch Intern Med. 2004;164(10):1066–76.

    Article  PubMed  Google Scholar 

  110. Gisondi P, Tessari G, Conti A, et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol. 2007;157(1):68–73.

    Article  CAS  PubMed  Google Scholar 

  111. Sommer DM, Jenisch S, Suchan M, Christophers E, Weichenthal M. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res. 2006;298(7):321–8.

    Article  PubMed  Google Scholar 

  112. Armstrong AW, Harskamp CT, Armstrong EJ. Psoriasis and metabolic syndrome: a systematic review and meta-analysis of observational studies. J Am Acad Dermatol. 2013;68(4):654–62.

    Article  PubMed  Google Scholar 

  113. Singh S, Young P, Armstrong AW. Relationship between psoriasis and metabolic syndrome: a systematic review. G Ital Dermatol Venereol. 2016;151(6):663–77.

    PubMed  Google Scholar 

  114. Kim HN, Han K, Park YG, Lee JH. Metabolic syndrome is associated with an increased risk of psoriasis: a nationwide population-based study. Metabolism. 2019;99:19–24.

    Article  CAS  PubMed  Google Scholar 

  115. Alsufyani MA, Golant AK, Lebwohl M. Psoriasis and the metabolic syndrome. Dermatol Ther. 2010;23(2):137–43.

    Article  PubMed  Google Scholar 

  116. Wolk K, Sabat R. Adipokines in psoriasis: an important link between skin inflammation and metabolic alterations. Rev Endocr Metab Disord. 2016;17(3):305–17.

    Article  CAS  PubMed  Google Scholar 

  117. Aghamohammadzadeh R, Withers S, Lynch F, Greenstein A, Malik R, Heagerty A. Perivascular adipose tissue from human systemic and coronary vessels: the emergence of a new pharmacotherapeutic target. Br J Pharmacol. 2012;165(3):670–82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  118. Despres JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature. 2006;444(7121):881–7.

    Article  CAS  PubMed  Google Scholar 

  119. Jones DP. Redefining oxidative stress. Antioxid Redox Signal. 2006;8(9–10):1865–79.

    Article  CAS  PubMed  Google Scholar 

  120. Cerman AA, Bozkurt S, Sav A, Tulunay A, Elbasi MO, Ergun T. Serum leptin levels, skin leptin and leptin receptor expression in psoriasis. Br J Dermatol. 2008;159(4):820–6.

    Article  CAS  PubMed  Google Scholar 

  121. Wang Y, Chen J, Zhao Y, Geng L, Song F, Chen HD. Psoriasis is associated with increased levels of serum leptin. Br J Dermatol. 2008;158(5):1134–5.

    Article  CAS  PubMed  Google Scholar 

  122. Hashmi S, Zeng QT. Role of interleukin-17 and interleukin-17-induced cytokines interleukin-6 and interleukin-8 in unstable coronary artery disease. Coron Artery Dis. 2006;17(8):699–706.

    Article  PubMed  Google Scholar 

  123. Women’s high CRP levels can predict hypertension. Healthcare Benchmarks Qual Improv. 2004;11(2):20–1.

    Google Scholar 

  124. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347(20):1557–65.

    Article  CAS  PubMed  Google Scholar 

  125. Ray KK, Cannon CP, Cairns R, Morrow DA, Ridker PM, Braunwald E. Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22. Arterioscler Thromb. 2009;29(3):424–30.

    Article  CAS  Google Scholar 

  126. Libby P. Inflammation in atherosclerosis. Nature. 2002;420(6917):868–74.

    Article  CAS  PubMed  Google Scholar 

  127. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352(16):1685–95.

    Article  CAS  PubMed  Google Scholar 

  128. Rosenson RS, Brewer HB Jr, Ansell BJ, et al. Dysfunctional HDL and atherosclerotic cardiovascular disease. Nat Rev Cardiol. 2016;13(1):48–60.

    Article  CAS  PubMed  Google Scholar 

  129. Sorokin AV, Kotani K, Elnabawi YA, et al. Association between oxidation-modified lipoproteins and coronary plaque in psoriasis. Circ Res. 2018;123(11):1244–54.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  130. Cervantes Gracia K, Llanas-Cornejo D, Husi H. CVD and oxidative stress. J Clin Med. 2017;6(2):22.

    Article  PubMed Central  CAS  Google Scholar 

  131. McDonald CJ, Calabresi P. Psoriasis and occlusive vascular disease. Br J Dermatol. 1978;99(5):469–75.

    Article  CAS  PubMed  Google Scholar 

  132. Krueger GG, Duvic M. Epidemiology of psoriasis: clinical issues. J Invest Dermatol. 1994;102(6):14S–8S.

    Article  CAS  PubMed  Google Scholar 

  133. Poikolainen K, Karvonen J, Pukkala E. Excess mortality related to alcohol and smoking among hospital-treated patients with psoriasis. Arch Dermatol. 1999;135(12):1490–3.

    Article  CAS  PubMed  Google Scholar 

  134. Mallbris L, Akre O, Granath F, et al. Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur J Epidemiol. 2004;19(3):225–30.

    Article  PubMed  Google Scholar 

  135. Mehta NN, Yu Y, Pinnelas R, et al. Attributable risk estimate of severe psoriasis on major cardiovascular events. Am J Med. 2011;124(8):775.e1–6.

    Article  PubMed  Google Scholar 

  136. Ahlehoff O, Gislason GH, Jørgensen CH, et al. Psoriasis and risk of atrial fibrillation and ischaemic stroke: a Danish nationwide cohort study. Eur Heart J. 2012;33(16):2054–64.

    Article  PubMed  Google Scholar 

  137. Prodanovich S, Kirsner RS, Kravetz JD, Ma F, Martinez L, Federman DG. Association of psoriasis with coronary artery, cerebrovascular, and peripheral vascular diseases and mortality. Arch Dermatol. 2009;145(6):700–3.

    Article  PubMed  Google Scholar 

  138. Abuabara K, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM. Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the U.K. Br J Dermatol. 2010;163(3):586–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  139. Mehta NN, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. Eur Heart J. 2010;31(8):1000–6.

    Article  PubMed  Google Scholar 

  140. Shiba M, Kato T, Izumi T, et al. Risk of myocardial infarction in patients with psoriasis: a cross-sectional patient-population study in a Japanese hospital. J Cardiol. 2019;73(4):276–9.

    Article  PubMed  Google Scholar 

  141. Xiao J, Chen LH, Tu YT, Deng XH, Tao J. Prevalence of myocardial infarction in patients with psoriasis in central China. J Eur Acad Dermatol Venereol. 2009;23(11):1311–5.

    Article  CAS  PubMed  Google Scholar 

  142. Lin HW, Wang KH, Lin HC, Lin HC. Increased risk of acute myocardial infarction in patients with psoriasis: a 5-year population-based study in Taiwan. J Am Acad Dermatol. 2011;64(3):495–501.

    Article  PubMed  Google Scholar 

  143. Levesque A, Lachaine J, Bissonnette R. Risk of myocardial infarction in Canadian patients with psoriasis: a retrospective cohort study. J Cutan Med Surg. 2013;17(6):398–403.

    Article  PubMed  Google Scholar 

  144. Ahlehoff O, Gislason GH, Lindhardsen J, et al. Prognosis following first-time myocardial infarction in patients with psoriasis: a Danish nationwide cohort study. J Intern Med. 2011;270(3):237–44.

    Article  CAS  PubMed  Google Scholar 

  145. Naik HB, Natarajan B, Stansky E, et al. Severity of psoriasis associates with aortic vascular inflammation detected by FDG PET/CT and neutrophil activation in a prospective observational study. Arterioscler Thromb Vasc Biol. 2015;35(12):2667–76.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  146. Egeberg A, Skov L, Joshi AA, et al. The relationship between duration of psoriasis, vascular inflammation, and cardiovascular events. J Am Acad Dermatol. 2017;77(4):650–656.e3.

    Article  PubMed  PubMed Central  Google Scholar 

  147. Ahlehoff O, Gislason GH, Charlot M, et al. Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study. J Int Med. 2011;270(2):147–57.

    Article  CAS  Google Scholar 

  148. Wee JS, Petrof G, Jackson K, Barker JN, Smith CH. Infliximab for the treatment of psoriasis in the UK: a 9 year experience of infusion reactions at a single centre. Br J Dermatol. 2012;167(2):411–6.

    Article  CAS  PubMed  Google Scholar 

  149. Armstrong EJ, Harskamp CT, Armstrong AW. Psoriasis and major adverse cardiovascular events: a systematic review and meta-analysis of observational studies. J Am Heart Assoc. 2013;2(2):e000062.

    Article  PubMed  PubMed Central  Google Scholar 

  150. Wakkee M, Herings RM, Nijsten T. Psoriasis may not be an independent risk factor for acute ischemic heart disease hospitalizations: results of a large population-based Dutch cohort. J Invest Dermatol. 2010;130(4):962–7.

    Article  CAS  PubMed  Google Scholar 

  151. Dowlatshahi EA, Wakkee M, Arends LR, Nijsten T. The prevalence and odds of depressive symptoms and clinical depression in psoriasis patients: a systematic review and meta-analysis. J Invest Dermatol. 2014;134(6):1542–51.

    Article  CAS  PubMed  Google Scholar 

  152. Stern RS, Huibregtse A. Very severe psoriasis is associated with increased noncardiovascular mortality but not with increased cardiovascular risk. J Invest Dermatol. 2011;131(5):1159–66.

    Article  CAS  PubMed  Google Scholar 

  153. Brauchli YB, Jick SS, Miret M, Meier CR. Psoriasis and risk of incident myocardial infarction, stroke or transient ischaemic attack: an inception cohort study with a nested case-control analysis. Br J Dermatol. 2009;160(5):1048–56.

    Article  CAS  PubMed  Google Scholar 

  154. Stern RS. Psoriasis is not a useful independent risk factor for cardiovascular disease. J Invest Dermatol. 2010;130(4):917–9.

    Article  CAS  PubMed  Google Scholar 

  155. Gelfand JM, Azfar RS, Mehta NN. Psoriasis and cardiovascular risk: strength in numbers. J Invest Dermatol. 2010;130(4):919–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  156. Gelfand JM, Mehta NN, Langan SM. Psoriasis and cardiovascular risk: strength in numbers, part II. J Invest Dermatol. 2011;131(5):1007–10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  157. Friedewald VE Jr, Cather JC, Gordon KB, Kavanaugh A, Ridker PM, Roberts WC. The editor’s roundtable: psoriasis, inflammation, and coronary artery disease. Am J Cardiol. 2008;101(8):1119–26.

    Article  PubMed  Google Scholar 

  158. Prodanovich S, Ma F, Taylor JR, Pezon C, Fasihi T, Kirsner RS. Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. J Am Acad Dermatol. 2005;52(2):262–7.

    Article  PubMed  Google Scholar 

  159. Boehncke S, Fichtlscherer S, Salgo R, et al. Systemic therapy of plaque-type psoriasis ameliorates endothelial cell function: results of a prospective longitudinal pilot trial. Arch Dermatol Res. 2011;303(6):381–8.

    Article  CAS  PubMed  Google Scholar 

  160. Wu JJ, Guerin A, Sundaram M, Dea K, Cloutier M, Mulani P. Cardiovascular event risk assessment in psoriasis patients treated with tumor necrosis factor-alpha inhibitors versus methotrexate. J Am Acad Dermatol. 2017;76(1):81–90.

    Article  CAS  PubMed  Google Scholar 

  161. Wu JJ, Sundaram M, Cloutier M, et al. The risk of cardiovascular events in psoriasis patients treated with tumor necrosis factor-alpha inhibitors versus phototherapy: an observational cohort study. J Am Acad Dermatol. 2018;79(1):60–8.

    Article  CAS  PubMed  Google Scholar 

  162. Ahlehoff O, Skov L, Gislason G, et al. Cardiovascular outcomes and systemic anti-inflammatory drugs in patients with severe psoriasis: 5-year follow-up of a Danish nationwide cohort. J Eur Acad Dermatol Venereol. 2015;29(6):1128–34.

    Article  CAS  PubMed  Google Scholar 

  163. Ellinghaus D, Ellinghaus E, Nair RP, et al. Combined analysis of genome-wide association studies for Crohn disease and psoriasis identifies seven shared susceptibility loci. Am J Hum Genet. 2012;90(4):636–47.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  164. Kim B-S, Lee W-K, Pak K, et al. Ustekinumab treatment is associated with decreased systemic and vascular inflammation in patients with moderate-to-severe psoriasis: feasibility study using 18F-fluorodeoxyglucose PET/CT. J Am Acad Dermatol. 2019;80(5):1322–31.

    Article  CAS  PubMed  Google Scholar 

  165. Brezinski EA, Follansbee MR, Armstrong EJ, Armstrong AW. Endothelial dysfunction and the effects of TNF inhibitors on the endothelium in psoriasis and psoriatic arthritis: a systematic review. Curr Pharm Des. 2014;20(4):513–28.

    Article  CAS  PubMed  Google Scholar 

  166. Lerman JB, Joshi AA, Chaturvedi A, et al. Coronary plaque characterization in psoriasis reveals high-risk features that improve after treatment in a prospective observational study. Circulation. 2017;136(3):263–76.

    Article  PubMed  PubMed Central  Google Scholar 

  167. Elnabawi YA, Dey AK, Goyal A, et al. Coronary artery plaque characteristics and treatment with biologic therapy in severe psoriasis: results from a prospective observational study. Cardiovasc Res. 2019;115(4):721–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  168. Mehta NN, Shin DB, Joshi AA, et al. Effect of 2 psoriasis treatments on vascular inflammation and novel inflammatory cardiovascular biomarkers: a randomized placebo-controlled trial. Circ Cardiovasc Imaging. 2018;11(6):e007394.

    Article  PubMed  PubMed Central  Google Scholar 

  169. Noe MH, Shin DB, Wan MT, Gelfand JM. Objective measures of psoriasis severity predict mortality: a prospective population-based cohort study. J Invest Dermatol. 2018;138(1):228–30.

    Article  CAS  PubMed  Google Scholar 

  170. Ahlehoff O, Gislason G, Lamberts M, et al. Risk of thromboembolism and fatal stroke in patients with psoriasis and nonvalvular atrial fibrillation: a Danish nationwide cohort study. J Int Med. 2015;277(4):447–55.

    Article  CAS  Google Scholar 

  171. Egeberg A, Khalid U, Gislason GH, Mallbris L, Skov L, Hansen PR. Association between depression and risk of atrial fibrillation and stroke in patients with psoriasis: a Danish nationwide cohort study. Br J Dermatol. 2015;173(2):471–9.

    Article  CAS  PubMed  Google Scholar 

  172. Parisi R, Rutter MK, Lunt M, et al. Psoriasis and the risk of major cardiovascular events: cohort study using the clinical practice research datalink. J Invest Dermatol. 2015;135(9):2189–97.

    Article  CAS  PubMed  Google Scholar 

  173. Rhee TM, Lee JH, Choi EK, et al. Increased risk of atrial fibrillation and thromboembolism in patients with severe psoriasis: a Nationwide Population-based Study. Sci Rep. 2017;7(1):9973.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  174. Chen YJ, Wu CY, Chen TJ, et al. The risk of cancer in patients with psoriasis: a population-based cohort study in Taiwan. J Am Acad Dermatol. 2011;65(1):84–91.

    Article  PubMed  Google Scholar 

  175. Chiesa Fuxench ZC, Shin DB, Ogdie Beatty A, Gelfand JM. The risk of cancer in patients with psoriasis: a population-based cohort study in the health improvement network. JAMA Dermatol. 2016;152(3):282–90.

    Article  PubMed  PubMed Central  Google Scholar 

  176. Pouplard C, Brenaut E, Horreau C, et al. Risk of cancer in psoriasis: a systematic review and meta-analysis of epidemiological studies. J Eur Acad Dermatol Venereol. 2013;27(Suppl 3):36–46.

    Article  PubMed  Google Scholar 

  177. Stern RS, Lunder EJ. Risk of squamous cell carcinoma and methoxsalen (psoralen) and UV-A radiation (PUVA). A meta-analysis. Arch Dermatol. 1998;134(12):1582–5.

    Article  CAS  PubMed  Google Scholar 

  178. Marcil I, Stern RS. Squamous-cell cancer of the skin in patients given PUVA and ciclosporin: nested cohort crossover study. Lancet. 2001;358(9287):1042–5.

    Article  CAS  PubMed  Google Scholar 

  179. Gelfand JM, Shin DB, Neimann AL, Wang X, Margolis DJ, Troxel AB. The risk of lymphoma in patients with psoriasis. J Invest Dermatol. 2006;126(10):2194–201.

    Article  CAS  PubMed  Google Scholar 

  180. Brauchli YB, Jick SS, Miret M, Meier CR. Psoriasis and risk of incident cancer: an inception cohort study with a nested case-control analysis. J Invest Dermatol. 2009;129(11):2604–12.

    Article  CAS  PubMed  Google Scholar 

  181. Margolis D, Bilker W, Hennessy S, Vittorio C, Santanna J, Strom BL. The risk of malignancy associated with psoriasis. Arch Dermatol. 2001;137(6):778–83.

    CAS  PubMed  Google Scholar 

  182. Lee JW, Jung KJ, Kim TG, et al. Risk of malignancy in patients with psoriasis: a 15-year nationwide population-based prospective cohort study in Korea. J Eur Acad Dermatol Venereol. 2019;33(12):2296–304.

    Article  CAS  PubMed  Google Scholar 

  183. Prizment AE, Alonso A, Folsom AR, et al. Association between psoriasis and incident cancer: the Iowa’s Women’s Health Study. Cancer Causes Control. 2011;22(7):1003–10.

    Article  PubMed  PubMed Central  Google Scholar 

  184. Kaushik SB, Lebwohl MG. Psoriasis: which therapy for which patient: psoriasis comorbidities and preferred systemic agents. J Am Acad Dermatol. 2019;80(1):27–40.

    Article  PubMed  Google Scholar 

  185. Kim N, Thrash B, Menter A. Comorbidities in psoriasis patients. Semin Cutan Med Surg. 2010;29(1):10–5.

    Article  CAS  PubMed  Google Scholar 

  186. Liu Y, Helms C, Liao W, et al. A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci. PLoS Genet. 2008;4(3):e1000041.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  187. Ni A, Chen H, Wu Y, Li W, Chen S, Li J. Expression of IRF-4 and IBP in skin lesions of patients with psoriasis vulgaris. J Huazhong Univ Sci Technolog Med Sci. 2012;32(2):287–90.

    Article  CAS  PubMed  Google Scholar 

  188. Hughes S, Williams SE, Turnberg LA. Crohn’s disease and psoriasis. N Engl J Med. 1983;308(2):101.

    Article  CAS  PubMed  Google Scholar 

  189. Yates VM, Watkinson G, Kelman A. Further evidence for an association between psoriasis, Crohn’s disease and ulcerative colitis. Br J Dermatol. 1982;106(3):323–30.

    Article  CAS  PubMed  Google Scholar 

  190. Lee FI, Bellary SV, Francis C. Increased occurrence of psoriasis in patients with Crohn’s disease and their relatives. Am J Gastroenterol. 1990;85(8):962–3.

    CAS  PubMed  Google Scholar 

  191. Hampe J, Schreiber S, Shaw SH, et al. A genomewide analysis provides evidence for novel linkages in inflammatory bowel disease in a large European cohort. Am J Hum Genet. 1999;64(3):808–16.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  192. Nair RP, Henseler T, Jenisch S, et al. Evidence for two psoriasis susceptibility loci (HLA and 17q) and two novel candidate regions (16q and 20p) by genome-wide scan. Hum Mol Genet. 1997;6(8):1349–56.

    Article  CAS  PubMed  Google Scholar 

  193. Patel DD, Kuchroo VK. Th17 cell pathway in human immunity: lessons from genetics and therapeutic interventions. Immunity. 2015;43(6):1040–51.

    Article  CAS  PubMed  Google Scholar 

  194. Andersen YMF, Wu J, Thyssen JP, Egeberg A. Chronological order of appearance of immune mediated inflammatory diseases relative to diagnosis of psoriasis. J Am Acad Dermatol. 2019;81(6):1283–91.

    Article  CAS  PubMed  Google Scholar 

  195. Li WQ, Han JL, Chan AT, Qureshi AA. Psoriasis, psoriatic arthritis and increased risk of incident Crohn’s disease in US women. Ann Rheum Dis. 2013;72(7):1200–5.

    Article  PubMed  Google Scholar 

  196. Cohen AD, Dreiher J, Birkenfeld S. Psoriasis associated with ulcerative colitis and Crohn’s disease. J Eur Acad Dermatol Venereol. 2009;23(5):561–5.

    Article  CAS  PubMed  Google Scholar 

  197. Eppinga H, Poortinga S, Thio HB, et al. Prevalence and phenotype of concurrent psoriasis and inflammatory bowel disease. Inflamm Bowel Dis. 2017;23(10):1783–9.

    Article  PubMed  Google Scholar 

  198. Makredes M, Robinson D Jr, Bala M, Kimball AB. The burden of autoimmune disease: a comparison of prevalence ratios in patients with psoriatic arthritis and psoriasis. J Am Acad Dermatol. 2009;61(3):405–10.

    Article  PubMed  Google Scholar 

  199. Rapp SR, Feldman SR, Exum ML, Fleischer AB Jr, Reboussin DM. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999;41(3 Pt 1):401–7.

    Article  CAS  PubMed  Google Scholar 

  200. Esposito M, Saraceno R, Giunta A, Maccarone M, Chimenti S. An Italian study on psoriasis and depression. Dermatology. 2006;212(2):123–7.

    Article  PubMed  Google Scholar 

  201. Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol. 2001;137(3):280–4.

    CAS  PubMed  Google Scholar 

  202. Gupta MA, Gupta AK. Depression and suicidal ideation in dermatology patients with acne, alopecia areata, atopic dermatitis and psoriasis. Br J Dermatol. 1998;139(5):846–50.

    Article  CAS  PubMed  Google Scholar 

  203. Singh S, Taylor C, Kornmehl H, Armstrong AW. Psoriasis and suicidality: a systematic review and meta-analysis. J Am Acad Dermatol. 2017;77(3):425–440.e2.

    Article  PubMed  Google Scholar 

  204. Howren MB, Lamkin DM, Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med. 2009;71(2):171–86.

    Article  CAS  PubMed  Google Scholar 

  205. Prather AA, Rabinovitz M, Pollock BG, Lotrich FE. Cytokine-induced depression during IFN-alpha treatment: the role of IL-6 and sleep quality. Brain Behav Immun. 2009;23(8):1109–16.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  206. Lotrich FE, El-Gabalawy H, Guenther LC, Ware CF. The role of inflammation in the pathophysiology of depression: different treatments and their effects. J Rheumatol Suppl. 2011;88:48–54.

    Article  CAS  PubMed  Google Scholar 

  207. Gimeno D, Kivimaki M, Brunner EJ, et al. Associations of C-reactive protein and interleukin-6 with cognitive symptoms of depression: 12-year follow-up of the Whitehall II study. Psychol Med. 2009;39(3):413–23.

    Article  CAS  PubMed  Google Scholar 

  208. Raison CL, Capuron L, Miller AH. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol. 2006;27(1):24–31.

    Article  CAS  PubMed  Google Scholar 

  209. Koo J, Marangell LB, Nakamura M, et al. Depression and suicidality in psoriasis: review of the literature including the cytokine theory of depression. J Eur Acad Dermatol Venereol. 2017;31(12):1999–2009.

    Article  CAS  PubMed  Google Scholar 

  210. Kim YK, Suh IB, Kim H, et al. The plasma levels of interleukin-12 in schizophrenia, major depression, and bipolar mania: effects of psychotropic drugs. Mol Psychiatry. 2002;7(10):1107–14.

    Article  CAS  PubMed  Google Scholar 

  211. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361(5):496–509.

    Article  CAS  PubMed  Google Scholar 

  212. Wu JJ, Penfold RB, Primatesta P, et al. The risk of depression, suicidal ideation and suicide attempt in patients with psoriasis, psoriatic arthritis or ankylosing spondylitis. J Eur Acad Dermatol Venereol. 2017;31(7):1168–75.

    Article  CAS  PubMed  Google Scholar 

  213. Egeberg A, Thyssen JP, Wu JJ, Skov L. Risk of first-time and recurrent depression in patients with psoriasis: a population-based cohort study. Br J Dermatol. 2019;180(1):116–21.

    Article  CAS  PubMed  Google Scholar 

  214. Dalgard FJ, Gieler U, Tomas-Aragones L, et al. The psychological burden of skin diseases: a cross-sectional multicenter study among dermatological out-patients in 13 European countries. J Invest Dermatol. 2015;135(4):984–91.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  215. Lewinson RT, Vallerand IA, Lowerison MW, et al. Depression is associated with an increased risk of psoriatic arthritis among patients with psoriasis: a population-based study. J Invest Dermatol. 2017;137(4):828–35.

    Article  CAS  PubMed  Google Scholar 

  216. Hu SC, Chen GS, Tu HP. Epidemiology of depression in patients with psoriasis: a Nationwide population-based cross-sectional study. Acta Derm Venereol. 2019;99(6):530–8.

    Article  PubMed  Google Scholar 

  217. Modalsli EH, Asvold BO, Snekvik I, Romundstad PR, Naldi L, Saunes M. The association between the clinical diversity of psoriasis and depressive symptoms: the HUNT study, Norway. J Eur Acad Dermatol Venereol. 2017;31(12):2062–8.

    Article  CAS  PubMed  Google Scholar 

  218. Richards HL, Fortune DG, Weidmann A, Sweeney SK, Griffiths CE. Detection of psychological distress in patients with psoriasis: low consensus between dermatologist and patient. Br J Dermatol. 2004;151(6):1227–33.

    Article  CAS  PubMed  Google Scholar 

  219. Feldman SR, Gottlieb AB, Bala M, et al. Infliximab improves health-related quality of life in the presence of comorbidities among patients with moderate-to-severe psoriasis. Br J Dermatol. 2008;159(3):704–10.

    Article  CAS  PubMed  Google Scholar 

  220. Langley RG, Feldman SR, Han C, et al. Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: results from a randomized, double-blind, placebo-controlled phase III trial. J Am Acad Dermatol. 2010;63(3):457–65.

    Article  CAS  PubMed  Google Scholar 

  221. Revicki DA, Menter A, Feldman S, Kimel M, Harnam N, Willian MK. Adalimumab improves health-related quality of life in patients with moderate to severe plaque psoriasis compared with the United States general population norms: results from a randomized, controlled phase III study. Health Qual Life Outcomes. 2008;6:75.

    Article  PubMed  PubMed Central  Google Scholar 

  222. Kleyn CE, McKie S, Ross AR, et al. Diminished neural and cognitive responses to facial expressions of disgust in patients with psoriasis: a functional magnetic resonance imaging study. J Invest Dermatol. 2009;129(11):2613–9.

    Article  CAS  PubMed  Google Scholar 

  223. Finlay AY, Khan GK. Dermatology life quality index (DLQI)—a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210–6.

    Article  CAS  PubMed  Google Scholar 

  224. Wu JJ, Feldman SR, Koo J, Marangell LB. Epidemiology of mental health comorbidity in psoriasis. J Dermatolog Treat. 2018;29(5):487–95.

    Article  CAS  PubMed  Google Scholar 

  225. Beck KM, Koo J. Brodalumab for the treatment of plaque psoriasis: up-to-date. Expert Opin Biol Ther. 2019;19(4):287–92.

    Article  PubMed  Google Scholar 

  226. Vakharia PP, Orrell KA, Lee D, et al. Apremilast and suicidality—a retrospective analysis of three large databases: the FAERS, EudraVigilance and a large single-centre US patient population. J Eur Acad Dermatol Venereol. 2017;31(10):e463–4.

    Article  CAS  PubMed  Google Scholar 

Download references

Funding Sources

None.

Author information

Authors and Affiliations

  1. Department of Dermatology, Leeds Teaching Hospitals, The University of Leeds, Leeds, UK

    Philip M. Laws

  2. Dermatological Sciences, Manchester NIHR Biomedical Research Centre, Salford Royal Hospital, The University of Manchester, Manchester, UK

    Philip M. Laws

  3. The Dermatology Centre, Leeds Teaching Hospitals, The University of Leeds, Leeds, UK

    Richard B. Warren

  4. The Dermatology Centre, Manchester NIHR Biomedical Research Centre, Salford Royal Hospital,The University of Manchester, Manchester, UK

    Richard B. Warren

Authors
  1. Philip M. Laws
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Richard B. Warren
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Richard B. Warren .

Editor information

Editors and Affiliations

  1. Department of Dermatology, Suite 11D, Icahn School of Medicine at Mount Sinai, New York, NY, USA

    Jeffrey M. Weinberg

  2. Icahn School of Medicine at Mount Sinai, New York, NY, USA

    Mark Lebwohl

Ethics declarations

PML has received honoraria and/or grants as an investigator, speaker, and/or advisory board member for AbbVie, Actelion, Almirall, Celgene, Janssen, Leo, Lilly, Novartis, UCB and Sanofi.

RBW has received Research Grants: AbbVie, Almirall, Amgen, Celgene, Janssen, Lilly, Leo, Novartis, Pfizer & UCB and Consulting Fees: AbbVie, Almirall, Amgen, Arena, Avillion, Bristol Myers Squibb, Boehringer Ingelheim, Celgene, Janssen, Leo, Lilly, Novartis, Pfizer, Sanofi & UCB

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Laws, P.M., Warren, R.B. (2021). Psoriasis and Comorbidities. In: Weinberg, J.M., Lebwohl, M. (eds) Advances in Psoriasis. Springer, Cham. https://doi.org/10.1007/978-3-030-54859-9_27

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-54859-9_27

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-54858-2

  • Online ISBN: 978-3-030-54859-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation